Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-02-15
DOI
10.3389/fimmu.2018.00283
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characterization of FcγRIIIA effector cells used in in vitro ADCC bioassay: Comparison of primary NK cells with engineered NK-92 and Jurkat T cells
- (2017) Yao-Te Hsieh et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Fully human CD19-specific chimeric antigen receptors for T-cell therapy
- (2017) D Sommermeyer et al. LEUKEMIA
- Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
- (2017) K H Chen et al. LEUKEMIA
- Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
- (2017) E Liu et al. LEUKEMIA
- Supply of promising T cell therapy is strained
- (2017) Jennifer Couzin-Frankel SCIENCE
- Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody
- (2017) Ying Chen et al. Oncotarget
- Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation
- (2016) Brian C. Shaffer et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation
- (2016) T. Sekine et al. BLOOD
- Driving gene-engineered T cell immunotherapy of cancer
- (2016) Laura A Johnson et al. CELL RESEARCH
- Cryopreservation has no effect on function of natural killer cells differentiated in vitro from umbilical cord blood CD34 + cells
- (2016) Anna Domogala et al. CYTOTHERAPY
- CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies
- (2016) Annette Romanski et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
- (2016) Partow Kebriaei et al. JOURNAL OF CLINICAL INVESTIGATION
- Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
- (2016) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival
- (2016) Ryan Alkins et al. NEURO-ONCOLOGY
- An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
- (2016) Caroline Jochems et al. Oncotarget
- Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
- (2016) Kevin H. Chen et al. Oncotarget
- A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases
- (2016) Xilin Chen et al. Oncotarget
- NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy
- (2015) Garnet Suck et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Natural Killer Cell Adoptive Transfer Therapy
- (2015) Zachary B. Davis et al. CANCER JOURNAL
- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
- (2015) Katrin Töpfer et al. JOURNAL OF IMMUNOLOGY
- ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
- (2015) Congcong Zhang et al. JNCI-Journal of the National Cancer Institute
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential
- (2015) Q Zhao et al. LEUKEMIA
- The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia
- (2015) R H Rouce et al. LEUKEMIA
- Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
- (2015) Kurt Schönfeld et al. MOLECULAR THERAPY
- Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
- (2015) Quan-shun Wang et al. MOLECULAR THERAPY
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
- (2015) E. Sotillo et al. Cancer Discovery
- A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity
- (2015) De-Gang Song et al. Oncotarget
- ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
- (2015) Congcong Zhang et al. JNCI-Journal of the National Cancer Institute
- Improving the safety of cell therapy with the TK-suicide gene
- (2015) Raffaella Greco et al. Frontiers in Pharmacology
- In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer
- (2015) Béatrice Clémenceau et al. Journal of Immunology Research
- The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer
- (2015) Katayoun Rezvani et al. Frontiers in Immunology
- Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival
- (2015) Sabrina Genßler et al. OncoImmunology
- CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
- (2015) Jianfeng Han et al. Scientific Reports
- A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells
- (2014) Eiji Kobayashi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15
- (2014) M. Imamura et al. BLOOD
- KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL
- (2014) L. Oevermann et al. BLOOD
- Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
- (2014) V. Bachanova et al. BLOOD
- Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease
- (2014) James O.J. Davies et al. CYTOTHERAPY
- Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia
- (2014) K. Stringaris et al. HAEMATOLOGICA
- Donor Killer Cell Ig-like Receptor B Haplotypes, Recipient HLA-C1, and HLA-C Mismatch Enhance the Clinical Benefit of Unrelated Transplantation for Acute Myelogenous Leukemia
- (2014) S. Cooley et al. JOURNAL OF IMMUNOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Natural killer cells in the treatment of high-risk acute leukaemia
- (2014) Franco Locatelli et al. SEMINARS IN IMMUNOLOGY
- Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
- (2014) Y. Chu et al. Cancer Immunology Research
- A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells
- (2013) Y.-H. Chang et al. CANCER RESEARCH
- Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy
- (2013) Isabela Pedroza-Pacheco et al. Cellular & Molecular Immunology
- Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
- (2013) M. Hudecek et al. CLINICAL CANCER RESEARCH
- Treatment of patients with advanced cancer with the natural killer cell line NK-92
- (2013) Torsten Tonn et al. CYTOTHERAPY
- Simplified process for the production of anti–CD19-CAR–engineered T cells
- (2013) Barbara Tumaini et al. CYTOTHERAPY
- Design and development of therapies using chimeric antigen receptor-expressing T cells
- (2013) Gianpietro Dotti et al. IMMUNOLOGICAL REVIEWS
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells
- (2013) Hua Jiang et al. Molecular Oncology
- Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
- (2013) David S. Ritchie et al. MOLECULAR THERAPY
- Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells
- (2013) Usanarat Anurathapan et al. MOLECULAR THERAPY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma
- (2013) Lihua E. Budde et al. PLoS One
- Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity
- (2013) Nina Shah et al. PLoS One
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- Expression of Chimeric Receptor CD4ζ by Natural Killer Cells Derived from Human Pluripotent Stem Cells Improves In Vitro Activity but Does Not Enhance Suppression of HIV Infection In Vivo
- (2013) Zhenya Ni et al. STEM CELLS
- Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy
- (2013) David A. Knorr et al. Stem Cells Translational Medicine
- CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors
- (2013) Vanesa Alonso-Camino et al. Molecular Therapy-Nucleic Acids
- Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
- (2013) Laurent Boissel et al. OncoImmunology
- Clinical Grade Purification and Expansion of NK Cell Products for an Optimized Manufacturing Protocol
- (2013) Ulrike Koehl et al. Frontiers in Oncology
- Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells
- (2012) S. Gill et al. BLOOD
- Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor
- (2012) Christiane Sahm et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Interleukin 2 in Cancer Therapy
- (2012) G. K. Antony et al. CURRENT MEDICINAL CHEMISTRY
- Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
- (2012) Natalia Lapteva et al. CYTOTHERAPY
- A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies
- (2012) Noriko Shimasaki et al. CYTOTHERAPY
- Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene Therapy
- (2012) Tolga Sutlu et al. HUMAN GENE THERAPY
- HLA-C–Dependent Prevention of Leukemia Relapse by Donor ActivatingKIR2DS1
- (2012) Jeffrey M. Venstrom et al. NEW ENGLAND JOURNAL OF MEDICINE
- The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES/CCL5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma
- (2012) JIANG LI et al. ONCOLOGY REPORTS
- Efficient Lentiviral Transduction of Human Mesenchymal Stem Cells That Preserves Proliferation and Differentiation Capabilities
- (2012) Paul Lin et al. Stem Cells Translational Medicine
- Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques
- (2011) T. A. Waldmann et al. BLOOD
- Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
- (2011) A. Curti et al. BLOOD
- A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
- (2011) X. Wang et al. BLOOD
- Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor
- (2011) D V Tassev et al. CANCER GENE THERAPY
- The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation
- (2011) Martha Luevano et al. HUMAN IMMUNOLOGY
- NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
- (2011) Ruth Esser et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
- (2011) Barbara Savoldo et al. JOURNAL OF CLINICAL INVESTIGATION
- Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens
- (2011) Laurent Boissel et al. LEUKEMIA & LYMPHOMA
- Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor
- (2011) Evripidis Lanitis et al. MOLECULAR THERAPY
- Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
- (2011) Antonio Di Stasi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation?
- (2010) Roel Willemze et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Donor KIR Genes 2DL5A, 2DS1 and 3DS1 Are Associated with a Reduced Rate of Leukemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for Acute Myeloid Leukemia but Not Other Hematologic Malignancies
- (2010) Kate Stringaris et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia
- (2010) S. Cooley et al. BLOOD
- NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects
- (2010) J. A. Olson et al. BLOOD
- Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education
- (2010) N. K. Bjorkstrom et al. BLOOD
- A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer
- (2010) Eleni G. Iliopoulou et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
- (2010) M. J. Besser et al. CLINICAL CANCER RESEARCH
- A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
- (2010) Melissa A. Geller et al. CYTOTHERAPY
- NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia
- (2010) Jeffrey E. Rubnitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
- (2010) V Hoyos et al. LEUKEMIA
- Generation of donor natural killer cells from CD34+ progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study
- (2009) S R Yoon et al. BONE MARROW TRANSPLANTATION
- Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method
- (2009) L Li et al. CANCER GENE THERAPY
- Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
- (2009) H. Fujisaki et al. CANCER RESEARCH
- Adoptive cell therapy for the treatment of patients with metastatic melanoma
- (2009) Steven A Rosenberg et al. CURRENT OPINION IN IMMUNOLOGY
- The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans
- (2009) Cameron S. Brandt et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity
- (2009) Y. Zhao et al. JOURNAL OF IMMUNOLOGY
- Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study
- (2009) Fabio Ciceri et al. LANCET ONCOLOGY
- KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia
- (2009) R Willemze et al. LEUKEMIA
- Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells
- (2009) Laurent Boissel et al. LEUKEMIA RESEARCH
- Moderate and severe adverse events associated with apheresis donations: incidences and risk factors
- (2009) Shan Yuan et al. TRANSFUSION
- Recovery and Safety Profiles of Marrow and PBSC Donors: Experience of the National Marrow Donor Program
- (2008) John P. Miller et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia
- (2008) S. Cooley et al. BLOOD
- Human natural killer cells
- (2008) M. A. Caligiuri BLOOD
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
- (2008) S. Arai et al. CYTOTHERAPY
- Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
- (2008) A. Kruschinski et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation
- (2007) Loredana Ruggeri et al. BLOOD CELLS MOLECULES AND DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now